Table 2.
Vascular parameters in participants with autosomal dominant polycystic kidney disease and control participants
| Variable | ADPKD, n=61 | Control, n=19 | P Value |
|---|---|---|---|
| FMDBA, mm | 0.26±0.15 | 0.32±0.13 | 0.15 |
| Baseline FMD diameter, mm | 3.5±0.7 | 3.2±0.5 | 0.13 |
| Shear rate, s−1 | 1075±459 | 1134±306 | 0.20 |
| Brachial artery dilation to nitroglycerin, % | 28.3±7.3 | 30.1±7.3 | 0.46 |
| Baseline nitroglycerin diameter, mm | 3.5±0.7 | 3.3±0.47 | 0.29 |
| Carotid-radial PWV, cm/s | 921±157 | 813±136 | <0.008 |
| Carotid artery compliance, (mm/mm Hg) ×10−1 | 0.12±0.04 | 0.12±0.04 | 0.50 |
| Carotid β-stiffness index, AU | 6.0±2.0 | 5.4±1.3 | 0.20 |
| Carotid IMT, mm | 0.48±0.08 | 0.45±0.05 | 0.23 |
| Carotid systolic BP, mm Hg | 119±15 | 106±13 | 0.001 |
| Mean arterial BP, mm Hg | 91±9 | 80±6 | <0.001 |
Data are mean±SD. In total, n=12 control participants and n=37 participants with ADPKD were administered nitroglycerin, and n=60 participants with ADPKD and all (n=19) control participants had measurements of carotid artery compliance, β-stiffness index, and carotid IMT. ADPKD, autosomal dominant polycystic kidney disease; FMDBA, brachial artery flow-mediated dilation; FMD, flow-mediated dilation; PWV, pulse-wave velocity; IMT, intimal medial thickness.